• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一例 COVID-19 复发 3 个月的病例中,未出现针对 SARS-CoV-2 的免疫应答。

Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.

机构信息

Department of Clinical Laboratory, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China.

Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.

出版信息

Infection. 2021 Feb;49(1):57-61. doi: 10.1007/s15010-020-01485-6. Epub 2020 Jul 28.

DOI:10.1007/s15010-020-01485-6
PMID:32725596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7386381/
Abstract

BACKGROUND

The viral persistence in patients with Coronavirus Disease 2019 (COVID-19) remains to be investigated.

METHODS

We investigated the viral loads, therapies, clinical features, and immune responses in a 70-year patient tested positive for SARS-CoV-2 for 3 months.

FINDINGS

The patient exhibited the highest prevalence of abnormal indices of clinical features and immune responses at the first admission, including fever (38.3 ℃), decreased lymphocytes (0.83 × 10/L) and serum potassium (3.1 mmol/L), as well as elevated serum creatinine (115 µmol/L), urea (8.6 mmol/L), and C-reactive protein (80 mg/L). By contrast, at the second and the third admission, these indices were all normal. Through three admissions, IL-2 increased from 0.14 pg/mL, 0.69 pg/mL, to 0.91 pg/mL, while IL-6 decreased from 11.78 pg/mL, 1.52 pg/mL, to 0.69 pg/mL, so did IL-10 from 5.13 pg/mL, 1.85 pg/mL, to 1.75 pg/mL. The steady declining trend was also found in TNF-α (1.49, 1.15, and 0.85 pg/mL) and IFN-γ (0.64, 0.42, and 0.27 pg/mL). The threshold cycle values of RT-PCR were 26.1, 30.5, and 23.5 for ORFlab gene, and 26.2, 30.6, and 22.7 for N gene, showing the patient had higher viral loads at the first and the third admission than during the middle term of the disease. The patient also showed substantially improved acute exudative lesions on the chest CT scanning images.

CONCLUSIONS

The patient displayed declining immune responses in spite of the viral shedding for 3 months. We inferred the declining immune responses might result from the segregation of the virus from the immune system.

摘要

背景

新型冠状病毒病 2019(COVID-19)患者的病毒持续存在仍待研究。

方法

我们研究了一位 70 岁 SARS-CoV-2 检测阳性患者的病毒载量、治疗、临床特征和免疫反应,该患者的病毒持续阳性时间为 3 个月。

发现

该患者在首次入院时表现出最高比例的异常临床特征和免疫反应指标,包括发热(38.3℃)、淋巴细胞减少(0.83×10/L)和血清钾降低(3.1mmol/L),以及血清肌酐升高(115μmol/L)、尿素(8.6mmol/L)和 C 反应蛋白升高(80mg/L)。相比之下,在第二次和第三次入院时,这些指标均正常。通过三次入院,IL-2 从 0.14pg/mL、0.69pg/mL 增加到 0.91pg/mL,而 IL-6 从 11.78pg/mL、1.52pg/mL 降低到 0.69pg/mL,IL-10 也从 5.13pg/mL、1.85pg/mL 降低到 1.75pg/mL。TNF-α(1.49、1.15 和 0.85pg/mL)和 IFN-γ(0.64、0.42 和 0.27pg/mL)也呈现出稳定下降的趋势。ORFlab 基因的 RT-PCR 阈值循环值分别为 26.1、30.5 和 23.5,N 基因分别为 26.2、30.6 和 22.7,表明患者在第一次和第三次入院时的病毒载量高于疾病中期。患者的胸部 CT 扫描图像上的急性渗出性病变也明显改善。

结论

尽管该患者病毒持续排出 3 个月,但免疫反应呈下降趋势。我们推断,免疫反应下降可能是由于病毒与免疫系统分离所致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26ae/7386381/3c33a4b2299c/15010_2020_1485_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26ae/7386381/3c33a4b2299c/15010_2020_1485_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26ae/7386381/3c33a4b2299c/15010_2020_1485_Fig1_HTML.jpg

相似文献

1
Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.在一例 COVID-19 复发 3 个月的病例中,未出现针对 SARS-CoV-2 的免疫应答。
Infection. 2021 Feb;49(1):57-61. doi: 10.1007/s15010-020-01485-6. Epub 2020 Jul 28.
2
Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019.2019冠状病毒病危重症患者中与脓毒症相关的严重白细胞介素-6风暴
Cell Mol Immunol. 2020 Oct;17(10):1092-1094. doi: 10.1038/s41423-020-00522-6. Epub 2020 Sep 11.
3
Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病(COVID-19)住院儿科患者的临床和免疫特征。
JAMA Netw Open. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895.
4
Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019.分析拭子中可检测到的 SARS-COV-2 RNA 与 2019 年冠状病毒病患者疾病严重程度的关系。
J Med Virol. 2021 Feb;93(2):794-802. doi: 10.1002/jmv.26307. Epub 2020 Jul 27.
5
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.促炎细胞因子与 COVID-19 患者病毒 RNA 持续脱落有关。
Clin Immunol. 2020 Dec;221:108611. doi: 10.1016/j.clim.2020.108611. Epub 2020 Oct 14.
6
Immune dysregulation and system pathology in COVID-19.COVID-19 中的免疫失调与系统病理学。
Virulence. 2021 Dec;12(1):918-936. doi: 10.1080/21505594.2021.1898790.
7
Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.无症状、轻度和重症有症状 SARS-CoV-2 感染患者的病毒载量、淋巴细胞亚群和细胞因子:一项回顾性研究。
Virol J. 2021 Jun 12;18(1):126. doi: 10.1186/s12985-021-01597-x.
8
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.利用 IL-2R/淋巴细胞预测 COVID-19 患者的临床进展。
Clin Exp Immunol. 2020 Jul;201(1):76-84. doi: 10.1111/cei.13450. Epub 2020 May 15.
9
An immune-based biomarker signature is associated with mortality in COVID-19 patients.基于免疫的生物标志物特征与 COVID-19 患者的死亡率相关。
JCI Insight. 2021 Jan 11;6(1):144455. doi: 10.1172/jci.insight.144455.
10
Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses.COVID-19 患者严重程度的相关因素:细胞因子/趋化因子浓度、病毒载量和抗体反应。
Am J Trop Med Hyg. 2020 Dec;103(6):2412-2418. doi: 10.4269/ajtmh.20-1110. Epub 2020 Oct 27.

引用本文的文献

1
Serum Proteomic Analysis for New Types of Long-Term Persistent COVID-19 Patients in Wuhan.武汉新型长期持续性 COVID-19 患者的血清蛋白质组学分析。
Microbiol Spectr. 2022 Dec 21;10(6):e0127022. doi: 10.1128/spectrum.01270-22. Epub 2022 Oct 31.
2
Evidence of SARS-CoV-2 reinfection: analysis of 35,000 subjects and overview of systematic reviews.SARS-CoV-2 再感染的证据:对 35000 名受试者的分析和系统评价综述。
Clin Exp Med. 2023 Aug;23(4):1213-1224. doi: 10.1007/s10238-022-00922-0. Epub 2022 Oct 26.
3
Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review.

本文引用的文献

1
Plasma therapy cured a COVID-19 patient with long duration of viral shedding for 49 days: The clinical features, laboratory tests, plasma therapy, and implications for public health management.血浆疗法治愈了一名病毒脱落持续49天的新冠肺炎患者:临床特征、实验室检查、血浆疗法及对公共卫生管理的启示
MedComm (2020). 2020 May 27;1(1):77-80. doi: 10.1002/mco2.2. eCollection 2020 Jun.
2
Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China.中国温州地区 2019 冠状病毒病患者低钾血症的评估及其临床特征。
JAMA Netw Open. 2020 Jun 1;3(6):e2011122. doi: 10.1001/jamanetworkopen.2020.11122.
3
新冠病毒二次感染患者的临床和流行病学特征:一项系统综述
New Microbes New Infect. 2022 Jul;48:101021. doi: 10.1016/j.nmni.2022.101021. Epub 2022 Aug 28.
4
The mystery of COVID-19 reinfections: A global systematic review and meta-analysis.新冠病毒再次感染之谜:一项全球系统评价与荟萃分析
Ann Med Surg (Lond). 2021 Dec;72:103130. doi: 10.1016/j.amsu.2021.103130. Epub 2021 Dec 4.
5
Recurrent SARS-CoV-2 infections and their potential risk to public health - a systematic review.反复感染 SARS-CoV-2 及其对公共健康的潜在风险——系统综述。
PLoS One. 2021 Dec 9;16(12):e0261221. doi: 10.1371/journal.pone.0261221. eCollection 2021.
6
Recognition of Long-COVID-19 Patients in a Canadian Tertiary Hospital Setting: A Retrospective Analysis of Their Clinical and Laboratory Characteristics.加拿大一家三级医院环境中长新冠患者的识别:对其临床和实验室特征的回顾性分析
Pathogens. 2021 Sep 26;10(10):1246. doi: 10.3390/pathogens10101246.
7
Updated pharmacological effects of Lonicerae japonicae flos, with a focus on its potential efficacy on coronavirus disease-2019 (COVID-19).更新的金银花的药理学作用,重点是其在 2019 冠状病毒病(COVID-19)方面的潜在疗效。
Curr Opin Pharmacol. 2021 Oct;60:200-207. doi: 10.1016/j.coph.2021.07.019. Epub 2021 Aug 10.
8
Recurrence, Reactivation, or Inflammatory Rebound of SARS-CoV-2 Infection With Acute Vestibular Symptoms: A Case Report and Revision of Literature.伴有急性前庭症状的新型冠状病毒感染复发、再激活或炎症反弹:病例报告及文献综述
Front Hum Neurosci. 2021 Aug 11;15:666468. doi: 10.3389/fnhum.2021.666468. eCollection 2021.
9
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis.COVID-19 再感染、复发和住院病例的流行病学特征:系统评价和荟萃分析。
J Med Virol. 2022 Jan;94(1):44-53. doi: 10.1002/jmv.27281. Epub 2021 Aug 27.
10
Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19.揭开 COVID-19 后急性后遗症之谜。
Front Immunol. 2021 Jun 30;12:686029. doi: 10.3389/fimmu.2021.686029. eCollection 2021.
Viral dynamics in asymptomatic patients with COVID-19.
无症状 COVID-19 患者的病毒动力学。
Int J Infect Dis. 2020 Jul;96:288-290. doi: 10.1016/j.ijid.2020.05.030. Epub 2020 May 11.
4
Recurrence of COVID-19 after recovery: a case report from Italy.新冠康复后复发:来自意大利的一例病例报告。
Infection. 2020 Dec;48(6):965-967. doi: 10.1007/s15010-020-01444-1. Epub 2020 May 16.
5
Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19).从新冠肺炎(COVID-19)中康复的年轻患者的直肠拭子呈阳性。
J Infect. 2020 Aug;81(2):e49-e52. doi: 10.1016/j.jinf.2020.04.023. Epub 2020 Apr 23.
6
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.COVID-19:一种新病毒,但熟悉的受体和细胞因子释放综合征。
Immunity. 2020 May 19;52(5):731-733. doi: 10.1016/j.immuni.2020.04.003. Epub 2020 Apr 22.
7
Temporal dynamics in viral shedding and transmissibility of COVID-19.新冠病毒脱落和传播的时间动态。
Nat Med. 2020 May;26(5):672-675. doi: 10.1038/s41591-020-0869-5. Epub 2020 Apr 15.
8
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.中国浙江 36 例 2019 冠状病毒病(COVID-19)患儿的临床和流行病学特征:一项观察性队列研究。
Lancet Infect Dis. 2020 Jun;20(6):689-696. doi: 10.1016/S1473-3099(20)30198-5. Epub 2020 Mar 25.
9
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.感染患者上呼吸道标本中的新型冠状病毒2型病毒载量
N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.
10
Biology and regulation of IL-2: from molecular mechanisms to human therapy.IL-2 的生物学和调控:从分子机制到人体治疗。
Nat Rev Immunol. 2018 Oct;18(10):648-659. doi: 10.1038/s41577-018-0046-y.